When new cancer therapies regularly become available more than half a year earlier in the US than in Europe, or get regulatory approval on one side of the Atlantic but not on the other, patients [more]
Computers are better than doctors at processing the large amounts of information involved in personalising treatments. But which decision-making tools can be relied on, and how can they best be used to help inform shared [more]
It’s long been the stuff of science fiction, but could the prospect of nanotechnology systems that deliver atomic bombs’ direct to cancer cells soon become reality? It’s a compelling vision: tiny particles, primed with a [more]
Less invasive than surgery and less toxic than systemic therapy, will the fast-growing specialty of interventional radiology join the big three’ as the fourth pillar of cancer care? Looking at the specialists in the front-line [more]
The odds that a woman will be told she needs a reoperation after conservative breast surgery vary between treatment centres, prompting calls for international guidelines and greater oversight of surgeons. For many women with [more]
Treating the right patient with the right therapy at the right time depends on having the right picture of every patient’s key biological markers. A number of initiatives are now springing up across Europe to [more]
With two novel immunotherapies approved and many more in the pipeline, is it time to announce that a new treatment modality has emerged? A class of therapy that has long held promise for treating cancer [more]
Conducting clinical trials in people with rare cancers is not easy when the number in a small trial do not add up to convincing evidence. Now some researchers are pressing for a new approach–using Bayesian [more]
Patient advocates and professionals alike believe these groundbreaking guidelines will raise standards of care, give much-needed structure to clinical research and improve awareness about a group of patients whose needs have been neglected for too [more]
The more we learn about biological variations and changes within a tumour the more daunting becomes the challenge of personalising therapies. On the road towards personalised cancer therapies, the tasks of identifying new targets and [more]
As our understanding of cancer increases are randomised controlled trials still the way to get the best drugs into use most quickly? Download full article
A single infrastructure for Europe’s rapidly evolving biobanks is urgently needed. But finding agreement on the ethics, language and operating standards is proving quite a challenge. Download full article
The concept of a genomic signature that can define any tumour according to its unique biology has been central to the emerging paradigm of personalised therapy. But how helpful are multi-gene assays in guiding treatment [more]